France Targets Shein, Temu With Fast-Fashion Fees 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Shein Shares Slide 9% in Hong Kong IPO Debut 
CIA-Linked Investor Helped Quantum Systems Expand in US 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Rejects Apple Trade Secret Theft Claims 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
Fort Lauderdale, Fla., March 19, 2018 -- CTI Clinical Trial & Consulting Services (CTI), a full-service, contract research organization (CRO) specializing in Early Phase, rare disease clinical trials, has expanded its existing partnership with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of patient-centric, clinical data management technology. Under the terms of a new multi-year, multi-million dollar agreement, CTI will use TrialMaster electronic data capture (EDC) solutions for studies during a four-year period. CTI conducts a high volume of diverse, complex and technically challenging studies around the globe.
“We’re excited to continue building our partnership with OmniComm,” said Todd Bonta, director of Clinical Data Management at CTI. “We have had a history of success with OmniComm’s TrialMaster suite, and we look forward to continuing to offer our sponsors the unique benefits provided by OmniComm’s solutions.”
OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to CTI. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
“OmniComm has been a valuable and flexible partner, helping CTI build a powerful suite of solutions for our Clinical Operations department,” said Louis Minham, senior director, Information Technologies at CTI. “We are happy to continue to partner with OmniComm as they expand their TrialMaster suite.”
Under the terms of the agreement, CTI will use TrialMaster, TriaIBuilder®, TriaIExplorer® AdHoc reporting, AutoEncoder®, OmniConnect, LabLoading and eLearning.
“Not only are we very proud of our established relationship with CTI, but also that we have earned their trust for increased business and commitment,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “It is a pleasure to work with a company that shares the same level of passion for problem solving for clients and seeks robust, scalable and innovative solutions to help meet expectations.”
About CTI Clinical Trial & Consulting Services
CTI Clinical Trial & Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization, including real world evidence. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hematology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. Please visit http://ctifacts.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems provides a critical role in enhancing patient lives by shortening time to market of
essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]
